Clinical Application of New CV Outcomes Data

Program Goals

Diabetes as a CV Risk Equivalent

The Need for CV Outcomes Studies

DPP-4 Inhibitors Mechanism of Action

SAVOR, EXAMINE, and TECOS Baseline Characteristics

SAVOR: Primary End Point

SAVOR: Secondary End Point

EXAMINE: Primary End Point

EXAMINE Primary End Point by Components

TECOS: Primary Composite CV Outcome Intent-to-Treat Analysis for Superiority

TECOS: Secondary Composite CV Outcome Intent-to-Treat Population

TECOS, EXAMINE, and SAVOR Hospitalization for HF

Ongoing CAROLINA and CARMELINA Trials

GLP-1 Receptor Agonists Mechanism of Action

Lixisenatide*

ELIXA Study Design

ELIXA No CV Risks of Benefits

Ongoing GLP-1 Receptor Agonist CV Outcomes Studies

SGLT2 Inhibitors Mechanism of Action

EMPA-REG OUTCOME® Study Design

EMPA-REG OUTCOME® Baseline Characteristics

EMPA-REG OUTCOME® Baseline CV Characteristics

EMPA-REG OUTCOME® HbA1c After 12 Weeks

All-cause mortality

All-cause mortality

EMPA-REG OUTCOME® Adverse Effects

Ongoing SGLT2 Inhibitor CV Outcomes Studies